SPLITVAC
Financiado
Harnessing the innate and adaptive immune system with targeted neoantigen based cancer vaccines
Immunotherapy for cancer has recently shown great clinical potential. However, only small percentages of patients do benefit from these therapies. The dual objective of the proposal is to understand and harness the immune system i...
Immunotherapy for cancer has recently shown great clinical potential. However, only small percentages of patients do benefit from these therapies. The dual objective of the proposal is to understand and harness the immune system in vivo to develop truly personalized (individualized) anti-cancer treatments and to develop powerful bioconjugation technologies to generate new and better biotherapeutics. The project objectives will be achieved through the combination of ProteoDesign’s site-specific bioconjugation technology, with recent advances in the field of immuno-oncology, particularly the importance of tumor specific mutations (neoantigens), as drivers of anti-tumor immunity. The therapeutic candidates that will be obtained as a result of the project are personalized and have the potential to treat cancer at the individual level. These therapies are based on the mutational landscape of any given tumor, and so they could be applied to multiple cancer indications. The proposal will face specific challenges regarding the development of complex personalized bio therapeutics.The project will be carried out through the collaboration of Dr. Vanhooren and Barcelona based biotech ProteoDesign. Dr. Vanhooren has extensive know-how and experience in the pre-clinical development of biologic-based drugs, and ProteoDesign has a proprietary technology for the discovery and development of new therapeutic bioconjugates. Through the present proposal bidirectional knowledge transfer will take place between the fellow and the host, thus enhancing know-how and skills on both sides. Dr. Vanhooren will be focused on leading the project, setting and adapting objectives, designing experiments, supervising the team and analyzing results. During the project and through a specific plan, ProteoDesign will provide Dr. Vanhooren experience and knowledge in key areas of biotechnology and pharma industries, as well as senior management, to allow her to grow into high responsibility positions.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2019-05-20
Fecha Fin: 2021-05-19
Fecha Fin: 2021-05-19
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-05-19
H2020
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
173K€
Líder del proyecto
PROTEODESIGN
No se ha especificado una descripción o un objeto social para esta compañía.
